12 Dec 2020
Evidence counts: latest data from Onyx one-month DAPT programme and renal denervation
Sponsored by Medtronic
Speakers:
A. Alenezi, M. Balghith
Summary
In this session you will get an overview of the subanalysis of Onyx One-month DAPT program which evaluated highly complex high-bleeding risk patients on one-month DAPT, followed by the latest evidence on renal denervation for the treatment of hypertension.
Learning Objectives
- To evaluate highly complex High Bleeding Risk (HBR) patients on one-month DAPT: subgroup analysis (AF, complex PCI & ACS)
- To evaluate the effects of renal denervation (RDN) on blood pressure in patients with hypertension